期刊文献+

医院感染鲍氏不动杆菌的分布特点及耐药性分析 被引量:3

Analysis of distribution and durg resistance in Acinetobacter baumannii of nosocomial infections
原文传递
导出
摘要 目的了解医院感染鲍氏不动杆菌的分布特点以及耐药性,为临床治疗鲍氏不动杆菌感染提供参考依据。方法收集医院2010年1月-2011年12月临床分离的鲍氏不动杆菌,采用K-B法进行药物敏感试验,利用SPSSB进行多因素logistic回归统计分析。结果 340株鲍氏不动杆菌主要分布在呼吸内科占17.94%、神经内科占17.94%,来源以痰为主占82.94%;对头孢哌酮/舒巴坦、头孢吡肟及多黏菌素B耐药率较低,分别为3.61%、3.61%及5.44%。结论应不断提高医务人员对鲍氏不动杆菌医院感染流行和耐药性趋势的认识,积极控制易感因素。 OBJECTIVE To explore the distribution characteristics and related factors of Acinetobacter baumannii nosocomial infections so as to Provide basis for clinical treatment of Acinetobacter baumannii infection. METHODS Clinical isolates of A. baumannii in our hospital were collected from January 2010 to December 2011; K-B method for drug susceptibility testing was used. Used SPSS to conduct the logistic regression analysis. RESULTS Of 340 A. baumannii , 17.94% and 17. 94 were mainly distributed in Respiratory Medicine. and department of Neurology; source sputum was mainly 82. 94% of specimen. The resistance rate to cefoperazone/sulbactam was 3.61%, polymyxin B 5. 44 %. CONCLUSION It is better to continue to improve the understanding of the Acinetobacter nosocomial infection prevalence and resistance trends among medical staff, which would actively control the risk factors.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2014年第5期1067-1069,共3页 Chinese Journal of Nosocomiology
基金 教育部人文社科基金项目(12YJA740084)
关键词 鲍氏不动杆菌 分布 耐药率 Acinetobacter baumannii distribution characteristics resistance rate risk factor
  • 相关文献

参考文献5

二级参考文献13

共引文献12

同被引文献27

  • 1Golden MP,Vikram HR.Extrapulmonary tuberculosis:an overview[J].Am Fam Physician,2005,72(9):1761-1768.
  • 2Celik SA.Nosocomial infections in neurosurgery intensive care units[J].J Clin Nurs,2004,13(6):741-747.
  • 3Yang M,Hu Z,Hu F.Nosocomial meningitis caused by Acinetobacter baumannii:risk factors and their impact on patient outcomes and treatments[J].Future Microbiol,2012,7(6):787-793.
  • 4Khemiri M,Bagais A,Becher SB,et al.Tuberculous meningitis in Bacille Calmette-Guerin-vaccinated children:clinical spectrum and outcome[J].J Child Neurol,2012,27(6):741-746.
  • 5Rahbar M, Mehrgan H, Aliakbari NH.Prevalence of antibi- otic-resistant Acinetobtwter baumannii in a 1000-bed ter- tiary care hospital in Tehran, Iran[J].Indian J Pathol Micro- biol, 2010,53 (2) : 290-293.
  • 6Evans BA, Hamouda A,Amyes SG.The rise of carbapenem- resistant A cinetobacter baumannitJ].Curr Pharm Des,2013, 19(2) :223-238.
  • 7Fonseca EL,Scheidegger E,Freitas FS,et a/.Carbapen- em-resistant A cinetobacter baumannii from Brazil: role of CarO alleles expression and blaOXA-23 gene[J].BMC Microbiol, 2013,13 (5) : 245.
  • 8Tada T, Miyoshi-Akiyama T, Kato Y,et a/.Emergence of 16S rRNA methylase-producing Acinetobacter bauman- nil and Pseudomonas aeruginosa isolates in hospitals in Vietnam[J].BMC Infect Dis, 2013,13 ( 1 ) : 251.
  • 9Yoon E J, Courvalin P, Grillot-Courvalin C.RND-type el- flux pumps in muhidrug-resistant clinical isolates ofA cine- tobacter b aumannii:major role for AdeABC overexpression and AdeRS mutations[J].Antimicrob Agents Chemother, 2013,57 (7) : 2989-2995.
  • 10Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii : emergence of a successful pathogen[J ]. Clin Microbiol Rev, 2008, 21 : 538-582.

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部